£18.6M
The financing was provided by Netherton Investments to advance extracellular matrix-targeted treatments for solid tumours and fibrosis.
Engitix
Engitix builds extracellular matrix datasets to develop targeted therapies for cancer and fibrosis.
£58.6MTotal raised
Engitix is a biotechnology company focused on extracellular matrix targets to develop therapies for cancer and fibrosis. It operates from London and maintains partnerships with major pharmaceutical firms.
Categories
Founders
Giuseppe Mazza
CEO
Giuseppe is co-founder and CEO of Engitix Therapeutics. He brings academic and research experience from UCL alongside his commercial roles.
LinkedInInvestors
- £18.6M
- £40.0M
Funding history
£40.0M
The financing round was co-led by Netherton Investments and Dompé farmaceutici.